Developing a new generation of therapies to protect, restore, and improve vision
Merck Completes Acquisition of EyeBio
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Eyebiotech Limited (EyeBio). EyeBio is now a wholly-owned subsidiary of Merck.
About Us
We created EyeBio to achieve a specific mission: to protect, restore, and improve vision for people living with eye diseases. Our work is urgent, because available therapies regularly fall short of improving vision or fail to provide durable, long-term solutions for patients.
EyeBio is a clinical-stage ophthalmology biotech company that brings together an experienced team of leaders, innovators, and entrepreneurs to develop a new generation of therapies for eye diseases. We understand what it takes to establish a new standard of care in ophthalmology. Our co-founders, Dr. David Guyer and Dr. Anthony P. Adamis, created and led the company that introduced the first anti-vascular endothelial growth factor (anti-VEGF) therapy for patients with age-related macular degeneration (AMD).
Working with a team of investors from several of the world’s leading healthcare fund managers, including SV Health Investors, Samsara BioCapital, Jeito Capital, MRL Ventures, and now Bain Capital, Omega Funds and Vertex Ventures, EyeBio has amassed the resources to develop and deliver new therapeutic solutions to patients with eye diseases. Together, EyeBio’s senior leadership and investors comprise an experienced team with a sharp focus on innovation in ophthalmology therapy.
We’re just getting started
Driven by a spirit of discovery and innovation, EyeBio is building a broad and diverse pipeline of advanced therapies for eye diseases. We invite you to learn more about our mission, our research and development programs, and our people.
Restoret
Learn more about Restoret, our clinical-stage lead asset targeting the Wnt pathway to treat retinal diseases.
The EyeBio Team
The EyeBio leadership team and board of directors have an unrivalled track record for developing ground-breaking ophthalmology therapies. The team’s deep experience and proven success in clinical development, combined with an extensive multinational clinical trial network, uniquely position EyeBio to efficiently and successfully advance new programs with the potential to redefine the treatment of eye diseases.
Management Team
Bryce Miller
Associate Vice President of Clinical Trial Strategy and Recruitment
Paul Stephens, Ph.D.
Senior Vice President, Chemistry, Manufacturing, and Controls
